LoadingLoadingLoading32 funds hold it.Insiders net buying.
Net buying: insiders sold $0 and bought $1M on the open market in 90 days (SEC Form 4). Congress: net selling of $15K to $50K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsLast report
Nov 3, 2026
Financial period
Third-Quarter 2026
Earnings per share
$0.74 expected
Revenue
$15.88B expected
Full-Year 2026 guidance
$62.00B to $64.00B
No comparable estimate
Estimates as of Nov 5, 2026
EPS expected
$0.63 to $0.83
Revenue expected
15 analysts
Last 30 days
Split both ways
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 27, 2026Reported Nov 3, 2026 | $0.87est. $0.74 | +18.26%beat | $16.58Best. $15.88B+4.45% | -0.4%from $16.65B |
| Jun 28, 2026Reported Aug 4, 2026 | $0.77est. $0.68 | +12.87%beat | $15.03Best. $14.39B+4.49% | +2.6%from $14.65B |
| Mar 29, 2026Reported May 5, 2026 | $0.75est. $0.72 | +3.93%beat | $14.45BSEC filing | +5.4%from $13.71B |
| Dec 31, 2025Reported Feb 3, 2026 | $0.66est. $0.57 | +16.18%beat | $17.56BAlpha Vantage | -1.2%from $17.76B |
| Sep 28, 2025Reported Nov 4, 2025 | $0.87est. $0.63 | +38.10%beat | $16.65BSEC filing | -5.9%from $17.70B |
| Jun 29, 2025Reported Aug 5, 2025 | $0.78est. $0.57 | +36.84%beat | $14.65BSEC filing | +10.3%from $13.28B |
| Mar 30, 2025Reported Apr 29, 2025 | $0.92est. $0.67 | +37.31%beat | $13.71BSEC filing | -7.8%from $14.88B |
| Dec 31, 2024Reported Feb 4, 2025 | $0.63est. $0.46 | +36.96%beat | $17.76BAlpha Vantage | +24.7%from $14.25B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $16.65B | $17.56B | $14.45B | $15.03B |
| Cost of what it sold | $4.17B | $5.27B | $3.55B | $4.09B |
| Gross profit | $12.48B | $12.29B | $10.90B | $10.94B |
| What it spent | ||||
| Research and development | $2.55B | $3.21B | $2.49B | $2.81B |
| Sales and admin | $3.19B | $4.08B | $2.96B | $3.41B |
| Other operating costs | $1.22B | $1.31B | $1.18B | $1.19B |
| Total operating expenses | $6.96B | $8.60B | $6.63B | $7.41B |
| What was left | ||||
| Operating profit | $5.53B | $3.69B | $4.27B | $3.54B |
| Interest on debt | $652.0M | $711.0M | $668.0M | $667.0M |
| Profit before tax | $3.33B | -$1.64B | $3.17B | -$653.0M |
| Tax | -$216.0M | -$2.0M | $461.0M | -$407.0M |
| Net profit | $3.54B | -$1.65B | $2.69B | -$248.0M |
| EBITDA | $5.65B | $756.0M | $5.45B | $1.64B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Form 10-Q PFIZER INC For: Sep 27
NeutralNov 3Pfizer Reports Earnings 📈 Shares Near Multi-Year Highs
BullishNov 3Pfizer Raises Forecast on Momentum With New Products
BullishNov 3Top Wall Street Forecasters Revamp Pfizer Expectations Ahead Of Q3 Earnings
NeutralNov 3Palvella Wins Priority FDA Review for Rare Disease Drug
Leans bullishNov 3Tempus AI (NASDAQ:TEM) Posts First Adjusted Profit as Oncology and Data Demand Accelerate
Leans bullishNov 3Teva Pharmaceutical Industries (TEVA) Dropped, So What Is Behind The Latest Attention?
NeutralNov 3VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test
Leans bullishNov 3
